AMENDMENTS TO THE CLAIMS

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



(I)

wherein

a and b are, independently, equal to 0 wherein the value of 0 represents a direct bond;

W is–N(R_2)-,

wherein

R_2 is

a) -alkyl;
b) – L_3-D-G;
c) –L_3-D-alkyl:
d) – L_3-D-aryl;
e) – L_3-D-heteroaryl;
f) – L_3-D-cycloalkyl;
g) – L_3-D-heterocyclyl;
h) – L_3-D-arylene-alkyl;
i) – L_3-D-alkylene-arylene-alkyl;
j) – L_3-D-alkylene-aryl;
k) –L_3-D-alkyl-G;
l) – L_3-D-aryl-G;

m) – L_3-D-heteroaryl-G;

n) – L_3-D-cycloalkyl-G;

o) – L_3-D-heterocyclyl-G;

p) – L_3-D-arylene-alkyl-G;

q) – L_3-D-alkylene-arylene-alkyl-G; or

r) – L_3-D-alkylene-aryl-G;

wherein

L_3 is an –alkylene, -alkenylene, or alkynylene;

D is a direct bond, $–CH_2$-, -O-, -N(R_5)-, -C(O)-, -CON(R_5)-, -N(R_6)C(O)-, -N(R_6)CON(R_5)-, -N(R_5)C(O)O-, -OC(O)N(R_5)-, -N(R_5)SO_2-, -SO_2N(R_5)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O_2)-, or -N(R_5)SO_2N(R_6)-, -N=N-, or -N(R_5)-N(R_6)-;

wherein

R_5 and R_6 are independently selected from the group consisting of:

-hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl; and

G is hydrogen, –CN, -SO_3H, -P(O)($OH)_2$, -P(O)(O-alkyl)(OH), $–CO_2$H, -CO_2-alkyl, an acid isostere, -NR_7R_8, or 

;

wherein

R_7 and R_8 are independently selected from the group consisting of: hydrogen, -alkyl, -L_4-E-alkyl, -L_4-E-aryl, -C(O)-alkyl, -C(O)-aryl, -SO_2-alkyl, -SO_2-aryl, and



;

wherein

R_9, R_{10}, and R_{11} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

L_4 is a direct bond, –alkylene, -alkenylene , or -alkynylene;

E is a direct bond, $–CH_2-$, -O-, $-N(R_{12})-$, $-C(O)-$, $-CON(R_{12})-$, $-N(R_{12})C(O)-$, $-N(R_{12})CON(R_{13})-$, $-N(R_{12})C(O)O-$, $-OC(O)N(R_{12})-$, $-N(R_{12})SO_2-$, $-SO_2N(R_{12})-$, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, $-S(O_2)-$, $-N(R_{12})SO_2N(R_{13})-$, -N=N-, or $-N(R_{12})-N(R_{13})-$

wherein

R_{12} and R_{13} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

R_1 is

a) -hydrogen;
b) –fluoro;
c) –chloro;
d) –bromo;
e) –iodo;
f) –cyano;
g) -alkyl;
h) –aryl;
i) -alkylene-aryl;

j) -heteroaryl;

k) –alkylkene-heteroaryl;

l) –cycloalkyl;

m) –alkylene-cycloalkyl

n) – heterocyclyl; or

o) – alkylene-heterocyclyl;

L_1 is selected from the group consisting of:



wherein ~~R_3 and R_4 are independently selected from the group consisting of: hydrogen, chloro, fluoro, bromo, alkyl, aryl, -alkylene-aryl, -cycloalkyl, -alkylene-cycloalkyl, -heterocyclyl, -alkylene-heterocyclyl, and -alkynylene;~~

Ar_1 is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro;

g) -perfluoroalkyl;

h) -J-R_{14};

i) -alkyl;

j) -aryl;

k) -heteroaryl;

l) -heterocyclyl;

m) -cycloalkyl;

n) -L_5-aryl;

o) - L_5-arylene-aryl;

p) - L_5-arylene-alkyl;

q) -arylene-alkyl;

r) -arylene-arylene-alkyl;

s) -J-alkyl;

t) -J-aryl;

u) -J-alkylene-aryl;

v) -J-arylene-alkyl;

w) -J-alkylene-arylene-aryl;

x) -J-arylene-arylene-aryl;

y) -J-alkylene-arylene-alkyl;

z) - L_5-J-alkylene-aryl;

aa) -arylene-J-alkyl;

bb) - L_5-J-aryl;

cc) - L_5-J-heteroaryl;

dd) - L_5-J-cycloalkyl;

ee) - L_5-J-heterocyclyl;

ff) - L_5-J-arylene-alkyl;

gg) - L_5-J-alkylene-arylene-alkyl;

hh) - L_5-J-alkyl;

ii) - L_5-J-R_{14}; and

jj) -arylene-J-R_{14};

wherein

L_5 is a direct bond, –alkylene, -alkenylene, or -alkynylene;

J is a direct bond, –CH_2-, -O-, -N(R_{15})-, -C(O)-, -CON(R_{15})-, -N(R_{15})C(O)-, -N(R_{15})CON(R_{16})-, -N(R_{15})C(O)O-, -OC(O)N(R_{15})-, -N(R_{15})SO_2-, -SO_2N(R_{15})-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O_2)-, -N(R_{15})SO_2N(R_{16})-, -N=N-, or -N(R_{15})-N(R_{16})- ,

wherein

R_{14}, R_{15}, and R_{16} are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl

Ar_2 is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

a) -fluoro;
b) -chloro;
c) -bromo;
d) -iodo;
e) -cyano;
f) -nitro;
g) -perfluoroalkyl;
h) -Q-R_{17};
i) -alkyl;
j) -aryl;
k) -heteroaryl;
l) -heterocyclyl;
m) -cycloalkyl;
n) -L_6-aryl;
o) -L_6-arylene-aryl;
p) -L_6-arylene-alkyl;
q) -arylene-alkyl;
r) -arylene-arylene-alkyl;
s) -Q-alkyl;
t) -Q-aryl;
u) -Q-alkylene-aryl;
v) -Q-arylene-alkyl;
w) -Q-alkylene-arylene-aryl;
x) -Q-arylene-arylene-aryl;
y) -Q-alkylene-arylene-alkyl;
z) -L_6-Q-alkylene-aryl;
aa) -arylene-Q-alkyl;
bb) -L_6-Q-aryl;
cc) -L_6-Q-heteroaryl;
dd) -L_6-Q-cycloalkyl;
ee) -L_6-Q-heterocyclyl;
ff) -L_6-Q-arylene-alkyl;

gg) -L_6-Q-alkylene-arylene-alkyl;

hh) -L_6-Q-alkyl;

ii) -L_6-Q-alkylene-aryl-R_{17};

jj) -L_6-Q-alkylene-heteroaryl-R_{17};

kk) -arylene-Q-alkylene-R_{17};

ll) -heteroarylene-Q-alkylene-R_{17};

mm) -L_6-Q-aryl-R_{17};

nn) -L_6-Q-heteroarylene-R_{17};

oo) -L_6-Q-heteroaryl-R_{17};

pp) –L_6-Q-cycloalkyl-R_{17};

qq) –L_6-Q-heterocyclyl-R_{17};

rr) –L_6-Q-arylene-alkyl-R_{17};

ss) –L_6-Q-heteroarylene-alkyl-R_{17};

tt) –L_6-Q-alkylene-arylene-alkyl-R_{17};

uu) –L_6-Q-alkylene-heteroarylene-alkyl-R_{17};

vv) –L_6-Q-alkylene-cycloalkylene-alkyl-R_{17};

ww) –L_6-Q-alkylene-heterocyclylene-alkyl-R_{17};

xx) –L_6-Q-alkyl-R_{17};

yy) –L_6-Q-R_{17};

zz) -arylene-Q-R_{17};

aaa) -heteroarylene-Q-R_{17};

bbb) -heterocyclylene-Q-R_{17};

ccc) -Q-alkylene-R_{17};

ddd) -Q-arylene-R_{17};

eee) -Q-heteroarylene-R_{17};

fff) -Q-alkylene-arylene-R_{17};

ggg) -Q-alkylene-heteroarylene-R_{17};

hhh) -Q-heteroarylene-alkylene- R_{17};

iii) -Q-arylene-alkylene- R_{17};

jjj) -Q-cycloalkylene-alkylene- R_{17};

kkk) -Q-heterocyclylene-alkylene- R_{17}

lll) -Q-alkylene-arylene-alkyl- R_{17};

mmm) -Q-alkylene-heteroarylene-alkyl- R_{17};

nnn)  ; and

ooo)  ;

wherein

L_6 is a direct bond, –alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, $–CH_2$-, -O-, $-N(R_{18})$-, -C(O)-, $-CON(R_{18})$-, $-N(R_{18})C(O)$-, $-N(R_{18})CON(R_{19})$-, $-N(R_{18})C(O)O$-, $-OC(O)N(R_{18})$-, $-N(R_{18})SO_2$-, $-SO_2N(R_{18})$-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, $-S(O_2)$-, $-N(R_{18})SO_2N(R_{19})$-, -N=N-, or $-N(R_{18})-N(R_{19})$-;

wherein

R_{18} and R_{19} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

V is



;

Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{17} is $-SO_3H$, $-P(O)(OH)_2$, -P(O)(O-alkyl)(OH), $–CO_2H$, $-CO_2$-alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl

L_2 is a direct bond,

T is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro;

g) -perfluoroalkyl;

h) -U-R_{22};

i) -alkyl;

j) -aryl;

k) -heteroaryl;

l) -heterocyclyl;

m) -cycloalkyl;

n) -L_7-aryl;

o) –L_7-arylene-aryl;

p) –L_7-arylene-alkyl;

q) -arylene-alkyl;

r) -arylene-arylene-alkyl;

s) -U-alkyl;

t) -U-aryl;

u) -U-alkylene-aryl;

v) -U-arylene-alkyl;

w) -U-alkylene-arylene-aryl;

x) -U-arylene-arylene-aryl;

y) -U-alkylene-arylene-alkyl;

z) –L_7-U-alkylene-aryl;

aa) -arylene-U-alkyl;

bb) –L_7-U-aryl;

cc) –L_7-U-heteroaryl;

dd) –L_7-U-cycloalkyl;

ee) -L_7-U-heterocyclyl;

ff) -L_7-U-arylene-alkyl;

gg) -L_7-U-alkylene-arylene-alkyl;

hh) -L_7-U-alkyl;

ii) -L_7-U-alkylene-aryl- R_{22};

jj) -L_7-U-alkylene-heteroaryl- R_{22};

kk) -arylene-U-alkylene- R_{22};

ll) -heteroarylene-U-alkylene- R_{22};

mm) -L_7-U-aryl- R_{22};

nn) -L_7-U-heteroarylene- R_{22};

oo) -L_7-U-heteroaryl- R_{22};

pp) -L_7-U-cycloalkyl- R_{22};

qq) –L_7-U-heterocyclyl- R_{22};

rr) –L_7-U-arylene-alkyl- R_{22};

ss) –L_7-U-heteroarylene-alkyl- R_{22};

tt) –L_7-U-alkylene-arylene-alkyl- R_{22};

uu) –L_7-U-alkylene-heteroarylene-alkyl- R_{22};

vv) –L_7-Q-alkylene-cycloalkylene-alkyl-R_{22};

ww) –L_7-Q-alkylene-heterocyclylene-alkyl-R_{22};

xx) –L_7-U-alkyl- R_{22};

yy) –L_7-U- R_{22};

zz) -arylene-U- R_{22};

aaa) -heteroarylene-U- R_{22};

bbb) -heterocyclylene-U- R_{22};

ccc) -U-alkylene- R_{22};

ddd) -U-arylene- R_{22};

eee) -U-heteroarylene- R_{22};

fff) -U-alkylene-arylene- R_{22};

ggg) -U-alkylene-heteroarylene- R_{22};

hhh) -U-heteroarylene-alkylene- R_{22};

iii) -U-arylene-alkylene- R_{22};

jjj) -U-cycloalkylene-alkylene- R_{22};

kkk) -U-heterocyclylene-alkylene- R_{22};

lll) -U-alkylene-arylene-alkyl- R_{22};

mmm) -U-alkylene-heteroarylene-alkyl- R_{22};

nnn) 

; and

ooo)  ;

wherein

L_7 is a direct bond, –alkylene, -alkenylene, or -alkynylene;

U is a direct bond, $-CH_2-$, -O-, $-N(R_{23})-$, -C(O)-, $-CON(R_{23})-$, $-N(R_{23})C(O)-$, $-N(R_{23})CON(R_{24})-$, $-N(R_{23})C(O)O-$, $-OC(O)N(R_{23})-$, $-N(R_{23})SO_2-$, $-SO_2N(R_{23})-$, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, $-S(O_2)-$, $-N(R_{23})SO_2N(R_{24})-$, -N=N-, or $-N(R_{23})-N(R_{24})-$;

wherein

R_{23} and R_{24} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is



;

Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{22} is $-SO_3H$, $-P(O)(OH)_2$, -P(O)(O-alkyl)(OH), $–CO_2H$, $-CO_2$-alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is $–N(R_2)-$, wherein R_2 is alkyl, or $–L_3$-D-alkylene-aryl, wherein L_3 is alkylene, and D is $-CO(NR_5)-$, wherein R_5 is hydrogen.

3. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R_1 is hydrogen or aryl.

4. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R_1 is hydrogen.

5-6. (Canceled)

7. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_1 is a phenyl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;
b) -chloro;
c) -bromo;
d) -iodo;
e) -cyano;
f) -nitro;
g) -perfluoroalkyl;
h) -J-R_{14};
i) -alkyl;
j) -aryl;
k) -heteroaryl;
l) -heterocyclyl;
m) -cycloalkyl;
n) -L_5-aryl;
o) - L_5-arylene-aryl;
p) - L_5-arylene-alkyl;
q) -arylene-alkyl;
r) -arylene-arylene-alkyl;
s) -J-alkyl;
t) -J-aryl;
u) -J-alkylene-aryl;
v) -J-arylene-alkyl;
w) -J-alkylene-arylene-aryl;
x) -J-arylene-arylene-aryl;
y) -J-alkylene-arylene-alkyl;

z) - L_5-J-alkylene-aryl;

aa) -arylene-J-alkyl;

bb) - L_5-J-aryl;

cc) - L_5-J-heteroaryl;

dd) - L_5-J-cycloalkyl;

ee) - L_5-J-heterocyclyl;

ff) - L_5-J-arylene-alkyl;

gg) - L_5-J-alkylene-arylene-alkyl;

hh) - L_5-J-alkyl;

ii) - L_5-J-R_{14}; and

jj) -arylene-J-R_{14};

wherein

L_5 is a direct bond, –alkylene, -alkenylene, or -alkynylene;

J is a direct bond, $-CH_2-$, -O-, $-N(R_{15})-$, $-C(O)-$, $-CON(R_{15})-$, $-N(R_{15})C(O)-$, $-N(R_{15})CON(R_{16})-$, $-N(R_{15})C(O)O-$, $-OC(O)N(R_{15})-$, $-N(R_{15})SO_2-$, $-SO_2N(R_{15})-$, $-C(O)-O-$, $-O-C(O)-$, -S-, $-S(O)-$, $-S(O_2)-$, $-N(R_{15})SO_2N(R_{16})-$, -N=N-, or $-N(R_{15})-N(R_{16})-$,

wherein

R_{14}, R_{15}, and R_{16} are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

8. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_1 is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) –nitro; and

g) -aryl.

9. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_1 is a phenyl group substituted 1 to 5 times, wherein the substituents are selected from the group consisting of: -chloro and -fluoro.

10. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenylene group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;
b) -chloro;
c) -bromo;
d) -iodo;
e) -cyano;
f) -nitro;
g) -perfluoroalkyl;
h) -Q-R_{17};
i) -alkyl;
j) -aryl;
k) -heteroaryl;
l) -heterocyclyl;
m) -cycloalkyl;
n) -L_6-aryl;
o) -L_6-arylene-aryl;
p) -L_6-arylene-alkyl;
q) -arylene-alkyl;
r) -arylene-arylene-alkyl;
s) -Q-alkyl;
t) -Q-aryl;
u) -Q-alkylene-aryl;
v) -Q-arylene-alkyl;
w) -Q-alkylene-arylene-aryl;
x) -Q-arylene-arylene-aryl;

y) -Q-alkylene-arylene-alkyl;

z) -L_6-Q-alkylene-aryl;

aa) -arylene-Q-alkyl;

bb) -L_6-Q-aryl;

cc) -L_6-Q-heteroaryl;

dd) -L_6-Q-cycloalkyl;

ee) -L_6-Q-heterocyclyl;

ff) -L_6-Q-arylene-alkyl;

gg) -L_6-Q-alkylene-arylene-alkyl;

hh) -L_6-Q-alkyl;

ii) -L_6-Q-alkylene-aryl-R_{17};

jj) -L_6-Q-alkylene-heteroaryl-R_{17};

kk) -arylene-Q-alkylene-R_{17};

ll) -heteroarylene-Q-alkylene-R_{17};

mm) -L_6-Q-aryl-R_{17};

nn) -L_6-Q-heteroarylene-R_{17};

oo) -L_6-Q-heteroaryl-R_{17};

pp) –L_6-Q-cycloalkyl-R_{17};

qq) –L_6-Q-heterocyclyl-R_{17};

rr) –L_6-Q-arylene-alkyl-R_{17};

ss) –L_6-Q-heteroarylene-alkyl-R_{17};

tt) –L_6-Q-alkylene-arylene-alkyl-R_{17};

uu) –L_6-Q-alkylene-heteroarylene-alkyl-R_{17};

vv) –L_6-Q-alkylene-cycloalkylene-alkyl-R_{17};

ww) –L_6-Q-alkylene-heterocyclylene-alkyl-R_{17};

xx) –L_6-Q-alkyl-R_{17};

yy) –L_6-Q-R_{17};

zz) -arylene-Q-R_{17};

aaa) -heteroarylene-Q-R_{17};

bbb) -heterocyclylene-Q-R_{17};

ccc) -Q-alkylene-R_{17};

ddd) -Q-arylene-R_{17};

eee) -Q-heteroarylene-R_{17};

fff) -Q-alkylene-arylene-R_{17};

ggg) -Q-alkylene-heteroarylene-R_{17};

hhh) -Q-heteroarylene-alkylene- R_{17};

iii) -Q-arylene-alkylene- R_{17};

jjj) -Q-cycloalkylene-alkylene- R_{17};

kkk) -Q-heterocyclylene-alkylene- R_{17}

lll) -Q-alkylene-arylene-alkyl- R_{17};

mmm) -Q-alkylene-heteroarylene-alkyl- R_{17};

nnn) 

; and

ooo) 

;

wherein

L_6 is a direct bond, –alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, $-CH_2-$, -O-, $-N(R_{18})-$, $-C(O)-$, $-CON(R_{18})-$, $-N(R_{18})C(O)-$, $-N(R_{18})CON(R_{19})-$, $-N(R_{18})C(O)O-$, $-OC(O)N(R_{18})-$, $-N(R_{18})SO_2-$, $-SO_2N(R_{18})-$, $-C(O)-O-$, $-O-C(O)-$, -S-, $-S(O)-$, $-S(O_2)-$, $-N(R_{18})SO_2N(R_{19})-$, -N=N-, or $-N(R_{18})-N(R_{19})-$;

wherein

R_{18} and R_{19} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

V is



;

Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{17} is $-SO_3H$, $-P(O)(OH)_2$, -P(O)(O-alkyl)(OH), $-CO_2H$, $-CO_2$-alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

11. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;
b) -chloro;
c) -bromo;
d) -iodo;
e) $-Q-R_{17}$;
f) -alkyl;
g) -aryl;
h) -arylene-alkyl;
i) -Q-alkyl; and
j) -arylene-Q-alkyl;

wherein

Q is $-CH_2-$, -O-, -C(O)-, or -C(O)-O-, and

R_{17} is: -hydrogen, -alkyl, -aryl, $-CO_2H$, or an acid isostere.

12. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenyl group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;
b) -chloro;
c) -bromo;
d) -iodo;
e) $-Q-R_{17}$;
f) -alkyl;

g) -phenyl;

h) -phenylene-alkyl;

i) -Q-alkyl; and

j) -phenylene-Q-alkyl;

wherein

Q is: $-CH_2-$, -O-, -C(O)-, or -C(O)-O-, and

R_{17} is: -hydrogen, -alkyl, –phenyl, or $-CO_2H$.

13-15. (Canceled)

16. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

a) -fluoro;

b) -chloro;

c) -bromo;

d) -iodo;

e) -cyano;

f) -nitro;

g) -perfluoroalkyl;

h) $-U-R_{22}$;

i) -alkyl;

j) -aryl;

k) -heteroaryl;

l) -heterocyclyl;

m) -cycloalkyl;

n) $-L_7$-aryl;

o) $-L_7$-arylene-aryl;

p) $-L_7$-arylene-alkyl;

q) -arylene-alkyl;

r) -arylene-arylene-alkyl;

s) -U-alkyl;

t) -U-aryl;

u) -U-alkylene-aryl;

v) -U-arylene-alkyl;

w) -U-alkylene-arylene-aryl;

x) -U-arylene-arylene-aryl;

y) -U-alkylene-arylene-alkyl;

z) $-L_7$-U-alkylene-aryl;

aa) -arylene-U-alkyl;

bb) $-L_7$-U-aryl;

cc) $-L_7$-U-heteroaryl;

dd) $-L_7$-U-cycloalkyl;

ee) $-L_7$-U-heterocyclyl;

ff) $-L_7$-U-arylene-alkyl;

gg) $-L_7$-U-alkylene-arylene-alkyl;

hh) $-L_7$-U-alkyl;

ii) $-L_7$-U-alkylene-aryl- R_{22};

jj) $-L_7$-U-alkylene-heteroaryl- R_{22};

kk) -arylene-U-alkylene- R_{22};

ll) -heteroarylene-U-alkylene- R_{22};

mm) $-L_7$-U-aryl- R_{22};

nn) $-L_7$-U-heteroarylene- R_{22};

oo) $-L_7$-U-heteroaryl- R_{22};

pp) $-L_7$-U-cycloalkyl- R_{22};

qq) $-L_7$-U-heterocyclyl- R_{22};

rr) $-L_7$-U-arylene-alkyl- R_{22};

ss) $-L_7$-U-heteroarylene-alkyl- R_{22};

tt) $-L_7$-U-alkylene-arylene-alkyl- R_{22};

uu) $-L_7$-U-alkylene-heteroarylene-alkyl- R_{22};

vv) $-L_7$-Q-alkylene-cycloalkylene-alkyl-R_{22};

ww) $-L_7$-Q-alkylene-heterocyclylene-alkyl-R_{22};

xx) $-L_7$-U-alkyl- R_{22};

yy) $-L_7$-U- R_{22};

zz) -arylene-U- R_{22};

aaa) -heteroarylene-U- R_{22};

bbb) -heterocyclylene-U- R_{22};

ccc) -U-alkylene- R_{22};

ddd) -U-arylene- R_{22};

eee) -U-heteroarylene- R_{22};

fff) -U-alkylene-arylene- R_{22};

ggg) -U-alkylene-heteroarylene- R_{22};

hhh) -U-heteroarylene-alkylene- R_{22};

iii) -U-arylene-alkylene- R_{22};

jjj) -U-cycloalkylene-alkylene- R_{22};

kkk) -U-heterocyclylene-alkylene- R_{22};

lll) -U-alkylene-arylene-alkyl- R_{22};

mmm) -U-alkylene-heteroarylene-alkyl- R_{22};

nnn)  ; and

ooo)  ;

wherein

L_7 is a direct bond, –alkylene, -alkenylene, or -alkynylene;

U is a direct bond, $-CH_2-$, -O-, $-N(R_{23})-$, -C(O)-, $-CON(R_{23})-$, $-N(R_{23})C(O)-$, $-N(R_{23})CON(R_{24})-$, $-N(R_{23})C(O)O-$, $-OC(O)N(R_{23})-$, $-N(R_{23})SO_2-$, $-SO_2N(R_{23})-$, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, $-S(O_2)-$, $-N(R_{23})SO_2N(R_{24})-$, -N=N-, or $-N(R_{23})-N(R_{24})-$;

wherein

R_{23} and R_{24} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is



, , or ;

Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{22} is $-SO_3H$, $-P(O)(OH)_2$, $-P(O)(O\text{-alkyl})(OH)$, $-CO_2H$, $-CO_2$-alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

17. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group substituted by -U-alkylene-R_{22}, wherein U is -O- or a direct bond, and R_{22} is $-CO_2H$ or an acid isostere.

18. (Currently Amended) The compound of Formula (I) according to claim 16 or a pharmaceutically acceptable salt or solvate thereof, wherein

a and b are equal to zero;

L_1 is  ;

Ar_2 is a phenylene group optionally substituted 1 time with a group consisting of: -Q-alkyl, wherein Q is -O-;

L_2 is a direct bond; and

T is an aryl group substituted with at least one substituent selected from the group consisting of:

a) -U-R_{22};

b) -U-alkylene-arylene-R_{22};

c) -U-alkylene-R_{22};

d) -U-arylene-R_{22};

e) -U-arylene-R_{22} wherein the arylene is substituted with at least one of a halogen, methanesulfonylamino, or trifluoromethanesulfonylamino group;

f) -U-arylene wherein the arylene is substituted with at least one trifluromethanesulfonylamino group;

g) -R_{22}; and

h) -halogen;

wherein R_{22} is $-CO_2H$ or an acid isotere.

19. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein

a and b are equal to zero;

R_1 is hydrogen;

W is $-N(R_2)-$, wherein R_2 is alkyl; and

Ar_1 is phenyl substituted 2 times wherein the substituent groups are –chloro.

20. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is $-N(R_2)-$, wherein

R_2 is -alkylene-arylene-G,

wherein

G is –CN, $-SO_3H$, $-P(O)(OH)_2$, -P(O)(O-alkyl)(OH), $-CO_2H$, $-CO_2$-alkyl, or an acid isostere.

21. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein a and b are equal to 0, and T, L_2, Ar_2, and L_1 together form a group selected from a group consisting of:

(E)-2-(1,1'-biphenyl-4-yl)vinyl,
(E)-2-(4'-methoxy-1,1'-biphenyl-4-yl)vinyl,
(E)-2-(3'-methoxy-1,1'-biphenyl-4-yl)vinyl,
(E)-2-(4'-carboxymethyloxy-1,1'-biphenyl-4-yl)vinyl,
(E)-2-(4'-(3-methoxycarbonyl-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl,
(E)-2-(4'-(3-carboxy-1-proploxy)-1,1'-biphenyl-4-yl)vinyl,
(E)-2-(4'-phenoxy-1,1'-biphenyl-4-yl)vinyl, and
(E)-2-(4'-benzyloxy-1,1'-biphenyl-4-yl)vinyl.

22. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_1 is: 2,4-dichlorophenyl.

23. (Currently Amended) The compound of Formula (I) according to claim 1, where the compound of Formula (I) is:

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-3-fluoro-biphenyl-4-yloxymethyl)-benzoic acid;

4-[4'-(2-{4-(2,4-dichloro-phenyl)-1-[(1-naphthalen-1-yl-ethylcarbamoyl)-methyl] 1H-imidazol-2-yl}-(E)-vinyl)-biphenyl-4-yloxy]-butyric acid;

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-butyric acid;

5-(4'-{2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-pentanoic acid

2-bromo-4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-benzoic acid;

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxymethyl)-benzoic acid;

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-benzoic acid;

2-bromo-4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-benzoic acid;

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-3-methanesulfonylamino-benzoic acid;

4-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-3-trifluoromethanesulfonyl-amino-benzoic acid;

5-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-2-methanesulfonylamino-benzoic acid;

5-(4'-{2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-2-trifluoromethane-sulfonylamino-benzoic acid; or

4-(4'-{2-[4-(2,4-Dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl}-biphenyl-4-yloxy)-butyric acid 2,2-dimethyl-propionyloxymethyl ester,

or a pharmaceutically acceptable salt or solvate thereof.

24. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1.

25. (Previously Presented) The pharmaceutical composition of claim 24, wherein said pharmaceutical composition is a topical formulation.

26-31. (Canceled).

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type I diabetes.

33. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type II diabetes.

34-37. (Canceled).

38. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat obesity.

39. (Canceled).

40. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat psoriasis.

41-63. (Canceled).